GlassScriptPhysician profile
Erik Mai
NPI 1912439571
$2,007.55
in general payments reported to CMS, 2019-2025
13 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $357 · 2020: $27.12 · 2021: $201 · 2022: $300 · 2023: $665 · 2024: $315 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,049 · Education: $71.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,049.45 |
| Education | $71.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $377.60 | 2023 | Korsuva, Veltassa |
| United Therapeutics Corporation | $302.52 | 2019-2021 | |
| Calliditas Therapeutics US INC. | $224.78 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $186.58 | 2023-2024 | |
| Alexion Pharmaceuticals, INC. | $178.55 | 2022-2024 | Soliris |
| E.R. Squibb & Sons, L.L.C. | $178.50 | 2019-2020 | |
| Penumbra, INC. | $141.72 | 2025 | Indigo System |
| Amgen INC. | $111.37 | 2023 | |
| Glaxosmithkline, LLC. | $105.75 | 2023 | Benlysta |
| Bayer Healthcare Pharmaceuticals INC. | $95.47 | 2022 | |
| Novo Nordisk INC | $47.03 | 2019-2020 | |
| Mylan Specialty L.P. | $46.23 | 2019 | |
| Merck Sharp & Dohme LLC | $11.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erik Mai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.